Vifor Pharma group announced that After 25 years of service the Executive Chairman of the Board of Directors of Vifor Pharma, Etienne Jornod, has decided not to renew his mandate, which expires at the Annual General Meeting of May 14, 2020. Stefan Schulze, currently President of the Executive Committee and Chief Operating Officer (COO) is appointed CEO for Vifor Pharma Group as of May 14, 2020. Stefan Schulze, an engineer by education, spent his professional career in the healthcare industry in the U.S. and Europe.

Stefan is COO and President of the Executive Committee of the Vifor Pharma Group since 2017. Etienne Jornodhas spent his entire professional life to date with the Vifor Pharma Group (formerly Galenica until it changed its name to Vifor Pharma in 2017). The Board of Directors proposes Jacques Theurillat to be elected by the shareholders as the new Chairman of the Board of Directors.

All other Board members will stand for re-election. Gilbert Achermann, currently Chairman of the Board of Straumann Group, is proposed to become member of the Boardto succeed Jacques Theurillat in the ARC (Audit and Risk Committee). Jacques Theurillat has an extensive experience in the pharmaceutical and healthcare industry.

Jacques Theurillat is a Swiss attorney-at-law and Swiss chartered tax expert and was elected to the BoD of Vifor Pharma in 2018.